Compare VBIO & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIO | VCIG |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.7M |
| IPO Year | 2021 | 2022 |
| Metric | VBIO | VCIG |
|---|---|---|
| Price | $2.30 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.1M | 695.2K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.20 |
| 52 Week High | $4.14 | $23.40 |
| Indicator | VBIO | VCIG |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 56.17 |
| Support Level | $0.30 | $0.43 |
| Resistance Level | $4.14 | $1.82 |
| Average True Range (ATR) | 0.59 | 0.33 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 51.91 | 40.97 |
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.